* AxoGen Inc AXGN.OQ AXGN.O is expected to show a rise
in
quarterly revenue when it reports results on November 8.
* The Alachua Florida-based company is expected to report
a
16.0% increase in revenue to $36.194 million from $31.2 million
a year ago, according to the mean estimate from 6 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for AxoGen Inc is for a
loss
of 12 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for AxoGen Inc
is
$20, above its last closing price of $10.69.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2022 -0.14 -0.14 -0.06 Beat 58.6
Mar. 31 2022 -0.16 -0.15 -0.20 Missed -30.4
Dec. 31 2021 -0.12 -0.13 -0.08 Beat 39.1
Sep. 30 2021 -0.14 -0.14 -0.09 Beat 34.4
Jun. -0.13 -0.13 -0.09 Beat 29.9
30 2021
Mar. 31 2021 -0.17 -0.16 -0.08 Beat 49.5
Dec. 31 2020 -0.11 -0.12 -0.08 Beat 35.6
Sep. 30 2020 -0.11 -0.14 0.04 Beat 128.2
This summary was machine generated November 4 at 19:38 GMT. All
figures in US dollars unless otherwise stated